ZEB1 and hepatocellular carcinoma: Targeting mitochondrial division in HCC by treatment with Mdivi-1 in combination with Sorafenib demonstrates a synergistic therapeutic effect in hepatocellular carcinoma (HCC) cell lines characterized by high ZEB1 expression.